MSAC recommends that from the evidence pertaining to brachytherapy for the treatment of prostate cancer, interim public funding should be supported for patients with prostate cancer:
- at clinical stages T1, T2a or T2b, with Gleason Scores of less than or equal to 6, prostate specific antigen (PSA) of less than or equal to 10 ng/ml, a gland volume less than 40 cc and with a life expectancy of more than 10 years; and
- where the treatment is conducted at approved sites.
This recommendation is to be reviewed no later than three years from the date of this report.